Oxopyridine Synthesis Route for High N/O-Alkylation Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing oxopyridine compounds, such as Bayer's BAY-2433334, face challenges in high racemization, low yield, complex purification, and poor N/O-alkylation selectivity, making them unsuitable for industrial scale-up.
Innovation Solution
A novel preparation method involving intermediates of Formula (II), (III), (IV), and (V) with specific functional groups, using milder bases and solvents, achieves high enantioselectivity and N/O-alkylation selectivity, reducing impurities and simplifying purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional synthesis methods (Bayer patent, WO 2014/154794) are used to prepare oxopyridine compounds, then the compounds can be obtained, but the synthesis suffers from high racemization, low yield, complex purification, and poor N/O-alkylation selectivity
Solution Approach 1:
The patent changes key reaction parameters including using milder bases (Cs2CO3, K2CO3, K3PO4) instead of strong bases, adjusting reaction temperatures (0-25°C), and modifying solvent systems to achieve both high enantioselectivity (98% ee) and high N/O-alkylation selectivity (30-40:1 ratio) while maintaining good yields
Solution Approach 2:
The patent introduces specific intermediates (Formulae II, III, IV, V) with protected hydroxyl groups that act as intermediaries in the synthesis pathway. These intermediates enable controlled N-alkylation before O-alkylation, achieving high selectivity and reducing racemization through staged reaction control
2Manufacturing precision
If lengthy linear synthetic strategies (9-step route from WO 2014/154794) are employed, then complete synthesis can be achieved, but the process is time-consuming and results in low overall yield due to high racemization
Solution Approach 1:
The patent segments the synthesis into modular steps with clearly defined intermediates (Formulae II-V). Each step is optimized independently, allowing for better control of stereochemistry and enabling parallel development of different reaction conditions to reduce overall synthesis time while maintaining high enantioselectivity
Solution Approach 2:
The patent performs preliminary protection of hydroxyl groups as tosylates or other protecting groups before alkylation reactions. This preliminary action prevents racemization during subsequent steps and enables high enantioselectivity to be maintained throughout the synthesis process
3Ease of manufacture
If condensation steps with poor N/O-alkylation selectivity are used, then reaction can proceed, but 10% undesired O-alkylated impurities are generated, increasing purification difficulty and product quality-control risk
Solution Approach 1:
The patent performs preliminary protection of the hydroxyl oxygen with tosyl or other protecting groups before N-alkylation. This preliminary action blocks O-alkylation pathways, ensuring high N/O-alkylation selectivity (30-40:1) and generating minimal impurities that require purification
Solution Approach 2:
The patent uses protected intermediate structures (Formulae III, IV, V) as intermediaries that direct alkylation to the nitrogen atom exclusively. These intermediates act as mediators that control regioselectivity, and after alkylation, the protecting groups are removed to give the final product with high purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method yields oxopyridine compounds with >98% enantiomeric excess, 30-40:1 N/O-alkylation selectivity, and 85-98% single-step yield, facilitating industrial-scale production with reduced costs and simplified purification.
Implementation Method 1
reacting an intermediate of Formula (II) or a pharmaceutically acceptable salt thereof with a compound of Formula (VI) to afford a compound of Formula (I)
Data Source
AI summary
A new route for preparing an oxopyridine compound as represented by formula (I) and a key intermediate thereof. The new route can greatly reduce the generation of isomer impurities, improve the selectivity of the reaction chirality and the selectivity of N/O-alkylation, increase the yield, avoid re-purification of a crude product, and reduce the cost, has a short production period, and is energy-saving and environmentally-friendly, and suitable for preparing a drug for treating and/or preventing diseases related to FXIa receptors, and particularly provides a new idea for preparing a drug for treating and/or preventing cerebrovascular artery diseases and/or peripheral artery diseases.